Netherton Syndrome LEKTI Microbe Patent - Azitra Inc
Summary
The USPTO granted US Patent 12606610B2 to Azitra Inc covering engineered microbes expressing recombinant LEKTI domains for the treatment of Netherton Syndrome. The patent contains 15 claims spanning compositions, methods, and kits. Inventors are Travis Michael Whitfill and Azim Momin Munivar.
What changed
The USPTO granted patent US12606610B2 to Azitra Inc on April 21, 2026. The patent covers engineered microbes expressing recombinant LEKTI domains and their use in treating Netherton Syndrome, a hereditary inflammatory skin disorder caused by SPINK5 gene mutations. The patent includes 15 claims covering compositions, methods, and kits.
For pharmaceutical and biotech companies developing treatments for rare dermatological conditions, this patent establishes intellectual property protection for a microbial-based LEKTI replacement therapy approach. Companies exploring similar live biotherapeutic or recombinant protein delivery methods for skin disorders should conduct freedom-to-operate analyses.
Archived snapshot
Apr 21, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions and methods for treatment of Netherton Syndrome with LEKTI expressing recombinant microbes
Grant US12606610B2 Kind: B2 Apr 21, 2026
Assignee
Azitra Inc
Inventors
Travis Michael Whitfill, Azim Momin Munivar
Abstract
The present disclosure provides, inter alia, engineered microbes expressing recombinant LEKTI domains that are effective to treat or ameliorate the symptoms of Netherton Syndrome. In certain embodiments, compositions, methods, and kits are provided comprising LEKTI domain expressing microbes.
CPC Classifications
A61K 35/744 A61K 35/745 A61K 35/747 A61K 38/57 A61K 9/0014 A61P 17/00 C07K 14/81 C07K 14/811 C07K 14/8135 C12N 15/746
Filing Date
2023-08-16
Application No.
18234588
Claims
15
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Grants - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.